Memantine Improves Depressive-like Behaviors via Kir6.1 Channel Inhibition in Olfactory Bulbectomized Mice. 2020

Shigeki Moriguchi, and Ryo Inagaki, and Hirotsugu Shimojo, and Yoshihiko Sugimura, and Kohji Fukunaga
Research Center for Pharmaceutical Development, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan; Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan. Electronic address: shigeki.moriguchi.a3@tohoku.ac.jp.

Aberrant depressive-like behaviors in olfactory bulbectomized (OBX) mice have been documented by previous studies. Here, we show that memantine enhances adult neurogenesis in the subgranular zone of the hippocampal dentate gyrus (DG) and improves depressive-like behaviors via inhibition of the ATP-sensitive potassium (KATP) channel in OBX mice. Treatment with memantine (1-3 mg/kg; per os (p.o.)) for 14 days significantly improved depressive-like behaviors in OBX mice, as assessed using the tail-suspension and forced-swim tests. Treatment with memantine also increased the number of BrdU-positive neurons in the DG of OBX mice. In the immunoblot analysis, memantine significantly increased phosphorylation of CaMKIV (Thr-196) and Akt (Ser-473), but not ERK (Thr-202/Tyr-204), in the DG of OBX mice. Furthermore, phosphorylation of GSK3β (Ser-9) and CREB (Ser-133), and BDNF protein expression levels increased in the DG of OBX mice, possibly accounting for the increased adult neurogenesis owing to Akt activation. In contrast, both the improvement of depressive-like behaviors and increase in BrdU-positive neurons in the DG following treatment with memantine were unapparent in OBX-treated Kir6.1 heterozygous (+/-) mice but not OBX-treated Kir6.2 heterozygous (+/-) mice. Furthermore, the increase in CaMKIV (Thr-196) and Akt (Ser-473) phosphorylation and BDNF protein expression levels was not observed in OBX-treated Kir6.1 +/- mice. Overall, our study shows that memantine improves OBX-induced depressive-like behaviors by increasing adult neurogenesis in the DG via Kir6.1 channel inhibition.

UI MeSH Term Description Entries
D008559 Memantine AMANTADINE derivative that has some dopaminergic effects. It has been proposed as an antiparkinson agent. 1,3-Dimethyl-5-aminoadamantane,1-Amino-3,5-dimethyladamantane,Axura,D-145,D145,Ebixa,Memantin,Memantine Hydrochloride,Namenda,D 145
D009830 Olfactory Bulb Ovoid body resting on the CRIBRIFORM PLATE of the ethmoid bone where the OLFACTORY NERVE terminates. The olfactory bulb contains several types of nerve cells including the mitral cells, on whose DENDRITES the olfactory nerve synapses, forming the olfactory glomeruli. The accessory olfactory bulb, which receives the projection from the VOMERONASAL ORGAN via the vomeronasal nerve, is also included here. Accessory Olfactory Bulb,Olfactory Tract,Bulbus Olfactorius,Lateral Olfactory Tract,Main Olfactory Bulb,Olfactory Glomerulus,Accessory Olfactory Bulbs,Bulb, Accessory Olfactory,Bulb, Main Olfactory,Bulb, Olfactory,Bulbs, Accessory Olfactory,Bulbs, Main Olfactory,Bulbs, Olfactory,Glomerulus, Olfactory,Lateral Olfactory Tracts,Main Olfactory Bulbs,Olfactorius, Bulbus,Olfactory Bulb, Accessory,Olfactory Bulb, Main,Olfactory Bulbs,Olfactory Bulbs, Accessory,Olfactory Bulbs, Main,Olfactory Tract, Lateral,Olfactory Tracts,Olfactory Tracts, Lateral,Tract, Lateral Olfactory,Tract, Olfactory,Tracts, Lateral Olfactory,Tracts, Olfactory
D003863 Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders. Depressive Symptoms,Emotional Depression,Depression, Emotional,Depressive Symptom,Symptom, Depressive
D006624 Hippocampus A curved elevation of GRAY MATTER extending the entire length of the floor of the TEMPORAL HORN of the LATERAL VENTRICLE (see also TEMPORAL LOBE). The hippocampus proper, subiculum, and DENTATE GYRUS constitute the hippocampal formation. Sometimes authors include the ENTORHINAL CORTEX in the hippocampal formation. Ammon Horn,Cornu Ammonis,Hippocampal Formation,Subiculum,Ammon's Horn,Hippocampus Proper,Ammons Horn,Formation, Hippocampal,Formations, Hippocampal,Hippocampal Formations,Hippocampus Propers,Horn, Ammon,Horn, Ammon's,Proper, Hippocampus,Propers, Hippocampus,Subiculums
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D054086 KATP Channels Heteromultimers of Kir6 channels (the pore portion) and sulfonylurea receptor (the regulatory portion) which affect function of the HEART; PANCREATIC BETA CELLS; and KIDNEY COLLECTING DUCTS. KATP channel blockers include GLIBENCLAMIDE and mitiglinide whereas openers include CROMAKALIM and minoxidil sulfate. ATP-Sensitive Potassium Channel,ATP-Sensitive Potassium Channels,KATP Channel,ATP Sensitive Potassium Channel,ATP Sensitive Potassium Channels,Channel, ATP-Sensitive Potassium,Channel, KATP,Channels, ATP-Sensitive Potassium,Channels, KATP,Potassium Channel, ATP-Sensitive,Potassium Channels, ATP-Sensitive

Related Publications

Shigeki Moriguchi, and Ryo Inagaki, and Hirotsugu Shimojo, and Yoshihiko Sugimura, and Kohji Fukunaga
July 2018, Neuropharmacology,
Shigeki Moriguchi, and Ryo Inagaki, and Hirotsugu Shimojo, and Yoshihiko Sugimura, and Kohji Fukunaga
January 2017, Pharmacology,
Shigeki Moriguchi, and Ryo Inagaki, and Hirotsugu Shimojo, and Yoshihiko Sugimura, and Kohji Fukunaga
July 2014, Neuroscience,
Shigeki Moriguchi, and Ryo Inagaki, and Hirotsugu Shimojo, and Yoshihiko Sugimura, and Kohji Fukunaga
January 2017, Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
Shigeki Moriguchi, and Ryo Inagaki, and Hirotsugu Shimojo, and Yoshihiko Sugimura, and Kohji Fukunaga
September 2022, Neuroscience research,
Shigeki Moriguchi, and Ryo Inagaki, and Hirotsugu Shimojo, and Yoshihiko Sugimura, and Kohji Fukunaga
May 2019, Phytotherapy research : PTR,
Shigeki Moriguchi, and Ryo Inagaki, and Hirotsugu Shimojo, and Yoshihiko Sugimura, and Kohji Fukunaga
May 2020, Journal of pharmacological sciences,
Shigeki Moriguchi, and Ryo Inagaki, and Hirotsugu Shimojo, and Yoshihiko Sugimura, and Kohji Fukunaga
July 2022, Neuroreport,
Shigeki Moriguchi, and Ryo Inagaki, and Hirotsugu Shimojo, and Yoshihiko Sugimura, and Kohji Fukunaga
September 2021, Neurochemistry international,
Shigeki Moriguchi, and Ryo Inagaki, and Hirotsugu Shimojo, and Yoshihiko Sugimura, and Kohji Fukunaga
April 2009, Brain research,
Copied contents to your clipboard!